Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Challenges with identification of angiogenesis biomarkers in cancer

This is a preview of subscription content, log in to check access.


  1. 1.

    Ellis LM, Reardon DA (2009) Cancer: the nuances of therapy. Nature 458:290–292

  2. 2.

    Roukos DH, Tzakos A, Zografos G (2009) Current concerns and challenges towards tailored anti-angiogenic therapy in cancer. Expert Rev Anticancer Ther 9:1413–1416

  3. 3.

    Shantha Kumara HM, Grieco MJ, Yan X, Kalady MF, Di Maggio V, Kim DG, Hyman N, Feingold DL, Whelan RL (2010) Minimally invasive colorectal resection for cancer is associated with a short-lived decrease in soluble Tie-2 receptor levels, which may transiently inhibit VEGF-mediated angiogenesis (via altered blood levels of free Ang-1 and Ang-2). Surg Endosc 24:2581–2587

  4. 4.

    Roukos DH (2009) Laparoscopic gastrectomy and personal genomics: high-volume surgeons and predictive biomedicine may govern the future for resectable gastric cancer. Ann Surg 250:650–651

  5. 5.

    Liakakos T, Roukos DH (2008) Is there any long-term benefit in quality of life after laparoscopy-assisted distal gastrectomy for gastric cancer? Surg Endosc 22:1402–1404

  6. 6.

    Katsios GC, Baltogiannis G, Roukos DH (2010) Laparoscopic surgery for gastric cancer: comparative-effectiveness research and future trends. Expert Rev Anticancer Ther 10:473–476

  7. 7.

    Liakakos T, Roukos D (2008) Laparoscopic gastrectomy: advances enable wide clinical application. Surg Endosc 22:1553–1555

  8. 8.

    Liakakos T, Roukos DH (2009) Randomized evidence for laparoscopic gastrectomy short-term quality of life improvement and challenges for improving long-term outcomes. Ann Surg 250:349–350

  9. 9.

    Ziogas D, Polychronidis A, Kanellos I, Roukos D (2009) Laparoscopic colectomy survival benefit for colon cancer: is evidence from a randomized trial true? Ann Surg 249:695–696

  10. 10.

    Ziogas D, Roukos D (2008) Robotic surgery for rectal cancer: may it improve also survival? Surg Endosc 22:1405–1406

  11. 11.

    Roukos DH (2010) Complete genome sequencing and network modeling to overcome trastuzumab resistance. Pharmacogenomics 11:1039–1043

  12. 12.

    Roukos DH (2010) Next-generation, genome sequencing-based biomarkers: concerns and challenges for medical practice. Biomark Med 4:583–586

  13. 13.

    Roukos DH, Katsios C, Liakakos T (2010) Genotype-phenotype map and molecular networks: a promising solution in overcoming colorectal cancer resistance to targeted treatment. Expert Rev Mol Diagn 10:541–545

  14. 14.

    Roukos DH (2010) Novel clinico-genome network modeling for revolutionizing genotype-phenotype-based personalized cancer care. Expert Rev Mol Diagn 10:33–48

  15. 15.

    Katsios C, Roukos DH (2010) Individual genomes and personalized medicine: life diversity and complexity. Per Med 7:347–350

  16. 16.

    Roukos DH (2010) Bionetworks-based personalized medicine versus comparative-effectiveness research or harmonization of both in cancer management? Expert Rev Mol Diagn 10(3):247–250

  17. 17.

    Ziogas D, Roukos DH (2009) CDH1 testing: can it predict the prophylactic or therapeutic nature of total gastrectomy in hereditary diffuse gastric cancer? Ann Surg Oncol 16:2678–2681

  18. 18.

    Roukos DH (2011) Measurable evidence of miRNAs as regulators of cancer networks and therapeutic targets. Expert Rev Med Devices 8(2):123–126

  19. 19.

    Roukos DH, Ziogas D (2010) From tumor size and HER2 status to systems oncology for very early breast cancer treatment. Expert Rev Anticancer Ther 10(2):123–128

  20. 20.

    Roukos DH (2009) Isolated tumor cells in breast cancer. N Engl J Med 361:1994–1995; author reply 1995–1996

  21. 21.

    Roukos DH, Ziogas D (2009) Human genetic and structural genomic variation: would genome-Wide association studies be the solution for cancer complexity like Alexander the great for the “gordian knot”? Ann Surg Oncol 16(3):774–775

  22. 22.

    Roukos DH, Kappas AM, Tsianos E (2002) Role of surgery in the prophylaxis of hereditary cancer syndromes. Ann Surg Oncol 9(7):607–609

  23. 23.

    Roukos DH, Kappas AM, Agnantis NJ (2003) Perspectives and risks of breast-conservation therapy for breast cancer. Ann Surg Oncol 10:718–721

  24. 24.

    Roukos DH, Agnanti NJ, Paraskevaidis E, Kappas AM (2002) Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations. Ann Surg Oncol 9(10):941–943

  25. 25.

    Roukos DH (2009) Breast cancer outcomes: the crucial role of the breast surgeon in the era of personal genetics and systems biology. Ann Surg 249(6):1067–1068

  26. 26.

    Roukos DH (2011) “Big” science: genome regulatory networks and novel molecular tools to improve health. Expert Rev Mol Diagn 11(2):123-126. doi: 10.1586/ERM/11.4

  27. 27.

    Roukos DH (2011) Cancer genome explosion and systems biology: impact on surgical oncology? Ann Surg Oncol 18(1):12–15

  28. 28.

    Roukos DH (2011) Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks. Pharmacogenomics J 11(2):81–92

  29. 29.

    Roukos DH (2010) Next-generation sequencing and epigenome technologies: potential medical applications. Expert Rev Med Devices 7(6):723–726

Download references


Eugenia Halkia and Nikolaos Kalinoglou have no conflicts of interest or financial ties to disclose.

Author information

Correspondence to Eugenia Halkia.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Halkia, E., Kalinoglou, N. Challenges with identification of angiogenesis biomarkers in cancer. Surg Endosc 25, 2769–2770 (2011).

Download citation


  • Vascular Endothelial Growth Factor
  • Bevacizumab
  • Oncologic Outcome
  • Antiangiogenic Therapy
  • Vascular Endothelial Growth Factor Signaling